Tarsus Pharmaceuticals, Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

TARS$73.83+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2025	2024	2025	2024
Revenues:
Product sales, net	$102,660	$40,813	$180,995	$65,533
License fees and collaboration revenue	—	—	—	2,894
Total revenues	102,660	40,813	180,995	68,427
Operating expenses:
Cost of sales	6,237	3,004	11,448	4,658
Research and development	15,594	12,319	30,003	24,385
Selling, general and administrative	103,013	58,792	188,008	110,370
Total operating expenses	124,844	74,115	229,459	139,413
Loss from operations before other income (expense)	(22,184)	(33,302)	(48,464)	(70,986)
Other income (expense):
Interest income	4,229	4,130	7,683	7,247
Interest expense	(2,240)	(2,109)	(4,453)	(3,092)
Loss on debt extinguishment	—	(1,944)	—	(1,944)
Other income (expense), net	(145)	(65)	(226)	(246)
Total other income (expense), net	1,844	12	3,004	1,965
Net loss	$(20,340)	$(33,290)	$(45,460)	$(69,021)
Unrealized gain (loss) on marketable securities and cash equivalents	(46)	(113)	(140)	(174)
Comprehensive loss	$(20,386)	$(33,403)	$(45,600)	$(69,195)
Net loss per share, basic and diluted	$(0.48)	$(0.88)	$(1.11)	$(1.89)
Weighted-average shares outstanding, basic and diluted	42,360,452	37,823,233	40,869,364	36,530,756

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.